Crystal structures of angiotensin-converting enzyme from Anopheles gambiae in its native form and with a bound inhibitor by Cashman, JS et al.
This is a repository copy of Crystal structures of angiotensin-converting enzyme from 
Anopheles gambiae in its native form and with a bound inhibitor.




Cashman, JS, Cozier, GE, Harrison, C et al. (2 more authors) (2019) Crystal structures of 
angiotensin-converting enzyme from Anopheles gambiae in its native form and with a 
bound inhibitor. The Biochemical journal, 476 (22). pp. 3505-3520. ISSN 0264-6021 
https://doi.org/10.1042/bcj20190635
Copyright © 2019 The Author(s). This is an author produced version of a paper published 




Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Crystal structures of angiotensin converting enzyme from Anopheles gambiae in 
its native form and with a bound inhibitor 
 
John S. Cashman1, Gyles E. Cozier1, Charlotte Harrison1, 
R. Elwyn Isaac2 and K. Ravi Acharya1,* 
 
1Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, 
U.K. 
2School of Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, U.K. 
 
*Correspondence: K. Ravi Acharya (bsskra@bath.ac.uk) 
 
Abstract 
The mosquitoes of the Anopheles and Aedes genus are some of the most deadly insects to 
humans because of their effectiveness as vectors of malaria and a range of arboviruses, 
including yellow fever, dengue, chikungunya, West Nile and zika. The use of insecticides 
from different chemical classes is a key component of the integrated strategy against An. 
gambiae and Ae. aegypti, but the problem of insecticide resistance means that new compounds 
with different modes of action are urgently needed to replace chemicals that fail to control 
resistant mosquito populations. We have previously shown that feeding inhibitors of peptidyl 
dipeptidase A to both An. gambiae nd Ae. aegypti mosquito larvae leads to stunted growth 
and mortality. However, these compounds were designed to inhibit the mammalian form of 
the enzyme (angiotensin converting enzyme, ACE) and hence can have lower potency and 
lack selectivity as inhibitors of the insect peptidase. Thus, for the development of inhibitors 
of practical value in killing mosquito larvae, it is important to design new compounds that are 
both potent and highly selective. Here we report the first structures of AnoACE2 from An. 
gambiae in its native form and with a bound human ACE inhibitor fosinoprilat. Comparison 
of these structures with human ACE (sACE) and an insect ACE homologue from Drosophila 
melanogaster (AnCE) revealed that AnoACE2 structure is more similar to AnCE. In addition, 
important elements that differ in these structures provide information that could potentially be 




Mosquitoes that flourish in tropical climates are responsible for transmitting various human viral and 
parasitic diseases. After a blood-meal, females lay eggs in water where the juveniles, called larvae, 
feed on particulate organic material. Within a few days, adults emerge from the water to continue the 
lifecycle. Disease transmission occurs when the adult female has multiple blood meals from different 
hosts. Controlling mosquito populations using insecticides is critical for reducing disease transmission 
but mosquitoes are showing increasing levels of resistance to existing chemicals and new insecticide 
classes are now needed [1-4]. 
In our search for a new class of insecticide to disrupt the mosquito life-cycle by targeting larval 
stages of the malaria and arbovirus vectors (Anopheles gambiae and Aedes aegypti respectively), we 
have identified an insect metallopeptidase (peptidyl dipeptidase-A), which is related to the 
mammalian blood pressure regulator angiotensin-1 converting enzyme (ACE), as an important 
molecular target [5, 6]. The insect enzyme (iACE) is a promiscuous peptidase that typically cleaves 
the penultimate C-terminal peptide bond of substrates and has been linked to the metabolism of 
peptide hormones involved in insect reproduction [6-8]. ACE inhibitors fed to adult anopheline 
mosquitoes (Anopheles stephensi and Anopheles gambiae) cause a drastic reduction in the numbers 
of eggs laid [9, 10]. In addition to their effects on adults, we have recently shown that ACE inhibitors 
are lethal to the developing larvae of both Anopheles gambiae and Aedes aegypti [11]. The ability of 
these compounds to reduce adult fecundity and to kill juvenile mosquitoes makes these enzymes 
attractive targets for the rational design of insect-selective inhibitors for the control of mosquito 
populations. 
Identification of the insect ACE gene family has expanded greatly in mosquitoes (in the 
Anopheles gambiae genome) to nine (AnoACEs 1–9) and there is evidence that four of them 
(AnoACE2, AnoACE3, AnoACE7 and AnoACE9) are up-regulated after blood meals prior to egg 
laying and expressed during larval development [12]. AnoACE7 and AnoACE9 are predicted to have 
a C-terminal hydrophobic sequence that can form a membrane anchor [12]. Since the majority of the 
peptidyl dipeptidase activity in homogenates of larvae is soluble, it is likely that the activity results 
from expression of one or both of AnoACE2 and AnoACE3 [11]. The amino acid sequence of both 
enzymes is highly conserved in A. gambiae [13] and the larval peptidase activity is inhibited by a 
variety of synthetic and natural compounds [11]. Of the synthetic inhibitors, captopril is the most 
potent (IC50 17 nM), followed by fosinoprilat (IC50 35 nM). Fosinopril, the esterified prodrug form of 
fosinoprilat, gives an expected considerably higher IC50 value (326 nM) compared to the free acid. 
Captopril is equally potent at inhibiting mammalian and iACEs, presumably because the relatively 
small size of the inhibitor allows easy access to the active sites of most enzymes in this family of 
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proteases. In addition, studies on the toxicity of the most potent inhibitor captopril and the pro-drug 
fosinopril on survival of 1st, 2nd and 3rd stage larvae of Anopheles gambiae showed that within 24 h 
captopril had killed >90 % of the early instar. Mortality was consistently high (>80 %) within 24 h of 
exposure of 1st, 2nd and 3rd instars of Anopheles gambiae to fosinopril [11]. These experimental data 
further confirmed the potential of AnoACE inhibitors as mosquito larvicides. However, all the 
compounds tested were established human ACE inhibitors and were used as proof of concept. 
AnoACE2 specific inhibitors will need to be developed for practical use. 
To determine the unique molecular features of AnoACE2, we now report the first crystal 
structure of AnoACE2 with the native enzyme at 2.2 Å resolution. This structure can provide the 
molecular basis for specific inhibition and form the basis for future inhibitor design. Comparison with 
the active site of the human ACE [known as somatic ACE (sACE) found in somatic tissues and with 
two domains (N and C) each containing an active site] (14-16)  and iACE from Drosophila 
melanogaster (AnCE) (17), highlights unique residues and subtle differences in the orientation of the 
side chains at different binding pockets in the active site of AnoACE2. In addition we present 
AnoACE2 in complex with fosinoprilat (2.5 Å) which confirms that ACE inhibitors bind to AnoACE2 
in the typical binding site seen for other ACE homologues and explains the high affinity of fosinoprilat 
for AnoACE2. 
 
Materials and methods 
AnoACE2 cloning 
AnoACE2 (UniProt A0NFU8) is a 638 residue protein containing a 26 residue signal sequence. 
Residues 27-638 were cloned into pOPINE pOPINTTGneo, pOPINHBM and pOPINHA using In-
Fusion Cloning technology (Takara Bio Europe) according to the manufacturer instructions. The 
native signal sequence (residues 1-26) was replaced with alternative signal sequences already pres nt 
in pOPINTTGneo, pOPINHBM and pOPINHA vectors, to enable secretion of the expressed protein 
into the cell culture medium. 
 
Protein expression and purification 
Sf9 cells were maintained in suspension in Sf-λ00™ II serum free medium (Thermo Scientific) at 
β7˚C with shaking at 140 rpm. Cells were passaged every γ-4 days according to the manufacturer 
instructions. Baculovirus stocks were prepared by co-transfecting cells with Prof. Ian Jones bacmid 
and AnoACE2 expression vectors using FuGENE® HD transfection reagent (Promega). To screen 
for protein expression, 3 mL cultures were seeded with 1 x 106 viable cells/mL and infected with 3 or 
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30µL P1 virus. Expression was optimised using time-course experiments and large-scale expression 
was performed in 2-4L cultures seeded with 1 x 106 viable cells/mL and infected with 3mL/L P2 virus. 
Cultures were incubated at β7˚C with shaking at 140 rpm for 72-90 hours and AnoACE2 was purified 
from 500 mL batches of protein-containing cell culture medium. Cultures were harvested and filtered 
using Sartoclear Dynamics® Lab V devices (Sartorius). The clarified medium was loaded directly 
onto a 5 mL HisTrap excel column (GE Life Sciences) and non-specifically bound proteins were 
removed by washing with 100 mL binding buffer (50 mM HEPES; 500 mM NaCl; pH 7.4), followed 
by 75 mL 5 % elution buffer (50 mM HEPES; 500 mM NaCl; 500 mM imidazole; pH 7.4). Elution 
was effected with a single step to 100 % elution buffer for 50 mL. Peak fractions were pooled, diluted 
1:4 with binding buffer (to reduce the imidazole concentration to approximately 100 mM), 
concentrated to a maximum volume of 750 µL and loaded onto a Superdex 10/300 column (GE Life 
Sciences) equilibrated with S200 buffer (50 mM HEPES; 150 mM NaCl; pH 7.4) to remove residual 
contaminants. Protein expression and purification were monitored by SDS PAGE and western blot 
with monoclonal mouse anti-his tag IgG (R&D Systems, MAB050) using a 1:5,000 dilution of the 0.5 
mg/mL stock in blocking solution. 
 
Activity and inhibition assays 
Enzyme assays were performed using the internally quenched fluorogenic peptide Abz-FRK(Dnp)-P 
(Enzo Life Sciences Ltd, Exeter, U.K.) as substrate for 25 ng of AnoACE2 in 200 µl of 100 mM 
HEPES buffer pH 7.5, 50 mM NaCl and 10 たM ZnCl2. The reaction was started by adding 2 µl of 5 
mM Abz-FRK(Dnp)-P in dimethyl sulfoxide to the buffer in wells of a 96-well black plastic plate 
(Corning Life Sciences, High Wycombe, U.K.) and the release of fluorescence on hydrolysis of the 
substrate was monitored continuously at 20oC using a FLUOstar Omega (BMG Labtech GmbH, 
Offenburg, Germany) with そex at 340 nm and そem set at 430 nm). For studying the effect of ACE 
inhibitors, the enzyme in the assay buffer was pre-incubated with inhibitor for 10 min prior to the 
addition of substrate. IC50 values and 95% confidence intervals (CI) for each inhibitor were determined 
using the non-linear regression curve fitting software [log(inhibitor) vs response] of GraphPad Prism 
7.01 GraphPad (Software, San Diego, CA, U.S.A.). 
 
Mass spectrometry 
20 µg samples of AnoACE2 were digested in solution using chymotrypsin and trypsin to increase 
sequence coverage. Proteins were reduced with 5 mM DTT for 30 min and alkylated with 20 mM 
iodoacetamide for 30 min. The samples were desalted and concentrated using chloroform-methanol 
concentration and digestion was performed in 1 M urea, Tris pH 7.8 using a 1:50 (enzyme:protein) 
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ratio. The trypsin digestions were performed at 37°C and chymotrypsin digestion was carried out at 
25°C overnight. 300 nL of peptides were injected in an Orbitrap Fusion™ Lumos™ Tribrid™ mass 
spectrometer (Thermo Fisher Scientific) and analysed using a 1 h gradient. Raw data were processed 
using Byonic™ software (Protein Metrics, CA). 
 
X-ray crystallographic analysis 
An ideal concentration range for crystallisation was determined using the pre-crystallisation test, as 
described by Hampton Research. The sitting drop vapor diffusion method with several commercially 
available screens (Molecular Dimensions) was used to determine crystallisation conditions for 
AnoACE2. One condition which yielded crystals in the presence of 55% v/v polypropylene glycol 
400, was optimised. For crystallisation with fosinopril, AnoACE2 was concentrated to between 5 and 
10 mg/mL and mixed with 20 mM inhibitor at a ratio of 4:1 respectively. Complexes were allowed to 
form at room temperature for 1 hour before adding to screens. 
Native AnoACE2 crystals were ultimately obtained using 10 mg/mL protein in 1:1 400 nL drops 
with 36% v/v polypropylene glycol, 10 mM ammonium sulfate, 30 mM sodium formate, 10 mM Tris 
pH 7.8, 0.γ% w/v け-PGA (Na+ form, LM), 0.3% w/v PEG 20,000. Fosinopril-bound AnoACE2 
crystals were grown in the same condition but containing a slightly higher polypropylene glycol 
concentration (43.2% v/v). Although fosinopril was used for the co-crystallisation, these prodrugs 
hydrolyse to their active form (in this case fosinoprilat) under the crystallisation conditions. 
X-ray diffraction data were collected on station i04 at the Diamond Light Source (Didcot, UK). 
Crystals were kept at constant temperature (100K) under nitrogen stream during data collection. 
Images were collected using a PILATUS3 6M detector (Dectris, Switzerland). Raw data images were 
indexed and integrated with DIALS [14], and then scaled using AIMLESS [15] from the CCP4 suite 
[16]. Initial phases for the native structure were obtained by molecular replacement with PHASER 
[17] using a model AnoACE2 structure based on cACE [11], and the solved native structure was used 
as the search model for the fosinoprilat AnoACE2 complex.  Further refinement was initially carried 
out using REFMAC5 [18] followed by PHENIX [19], with COOT [20] used for rounds of manual 
model building. Inhibitor, zinc ion and water molecules were added based on electron density in the 
Fo-Fc Fourier difference map. MolProbity [21] was used to help validate the structures. 
Crystallographic data statistics are summarized in Table 2. All figures showing the crystal structures 





Expression, purification of AnoACE2 
AnoACE2 cDNA was cloned into various pOPIN vectors using the In-Fusion® HD Cloning Plus kit 
(Takara Clontech). The highest protein yields were attained from Sf9 cells using the pOPINHBM-
AnoACE2 construct. The protein was estimated to be 20% glycosylated by weight, as judged by 
mobility on SDS polyacrylamide gels. The secreted protein following expression, was purified 
directly by immobilised metal affinity and size exclusion chromatography. This method reliably yields 
2.1 mg protein per L of culture with >95 % purity.  
 
AnoACE2 activity 
The peptidyl dipeptidase activity of the purified mosquito protein was confirmed by using the FRET 
substrate Abz-FRK(Dnp)-P and by titrating various human ACE inhibitors (known ACE inhibitors 
have been used as proof of concept for AnoACE2 inhibition) to generate IC50 data (Table 1). Four 
inhibitors tested showed high potency as revealed by the low nM values, with lisinopril being the 
weakest, although still a high affinity inhibitor with an IC50 of 16 nM. Captopril showed a more potent 
IC50 of 5.2 nM. In contrast to the activity assay previously performed using the soluble fraction of 
homogenised mosquito larvae which showed that captopril was the most potent of the inhibitors tested 
[11], the assay using recombinant AnoACE2 showed that fosinoprilat had a slightly more potent IC50 
(1.5 nM) than that observed for captopril. Enalaprilat had a similarly potent IC50 of 2.0 nM. け-PGA, 
which is present in the crystallisation buffer, was found to interact with native AnoACE2 in the active 
site (see below). It inhibited the enzyme activity with an IC50 of 0.2 % w/v, which is below the 0.3 %
w/v concentration used in the crystallization buffer.  
 
AnoACE2 glycosylation 
Glycosylation of human ACE proteins has been shown to be important for peptidase activity [24] and 
this is likely to be the case for iACEs. Sequence analysis using Prot pi to identify the number of 
asparagine residues present within the glycosylation consensus sequence Asn–X–Ser/Thr (where X is 
any residue apart from proline) showed that AnoACE2 has six potential N-glycosylation sites 
(residues 69, 74, 106, 187, 212 and 327) (Fig. 1). We used mass spectrometry to determine which of 
these sites had N-glycosylations. Digestion of AnoACE2 with chymotrypsin and trypsin allowed for 
44.9 % and 45.3 % sequence coverage in the MS/MS spectra, respectively (Fig. 1A). Using both 
enzymes gave a total of 65.5 % sequence coverage, which included all potential N-glycosylation ites. 
The data revealed that five out of the six potential sites were glycosylated (residues 69, 106, 187, 212 
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and 327, but not residue 74) (Fig. 1B,C). This information will be useful for any future work to
examine which, if any, glycosylation sites are required for enzyme activity. 
 
Crystallisation of AnoACE2 
Crystal growth was initially tested using several commercially available crystallization screen  
(Molecular Dimensions). One condition that yielded long, rod-like crystals (55 % v/v polypropylene 
glycol 400) was optimised through additive and seeding experiments, and adjustments to the protein 
and precipitant concentrations, which resulted in significant improvements with the quality of crystals. 
X-ray diffraction data were collected at Diamond Light Source beamline i04 for both native AnoACE2 
and in complex with fosinoprilat.  
 
Overall structure of AnoACE2 
Both native AnoACE2 and the fosinoprilat-AnoACE2 complex structures belong to P6222 space 
group with a monomer in the asymmetric unit (Fig. 2A,B). The native AnoACE2 was determined to 
2.2 Å with a conventional R-factor (Rcryst) of 0.194 and a free R-factor (Rfree) of 0.241 (Table 2), 
whereas fosinoprilat-AnoACE2 complex was refined to 2.5 Å with an Rcryst of 0.294 and Rfree of 0.337 
respectively. The R-factors for the fosinoprilat-AnoACE2 complex indicate that the X-ray diffraction 
data from this crystal is not of the same quality as for the native structure. Careful examination of the 
data with tests for twinning, alternative space groups etc were performed, but no twinning was 
detected, and alternative space groups such as P3212 produced significantly worse R-factors and 
electron density maps. The lower quality data for the fosinoprilat-AnoACE2 complex is most likely 
due to just a lower quality crystal. The vast majority of AnoACE2 crystals tested showed low 
resolution (less than 4 Å) diffraction, even after extensive screening for better conditions. Many 
crystals of both native and ligand bound had to be tested to obtain the data presented here. This 
suggests that binding of fosinoprilat probably does not cause a reduction in crystal quality. To produce 
the best model from the fosinoprilat-AnoACE2 complex data, extensive rounds of manual rebuilding 
and refinement were performed, and the ‘Optimize x-ray/stereochemistry weight’ option in Phenix 
was selected for the refinement. While this increased the restraints, giving the effect of low bond 
length and angle root-mean-square deviation values, it did give the best model structure overall. Even 
so, the Ramachandran statistics are not as good as for the native structure, although they are still 99.8% 
within allowed regions. Analysis of the Ramachandran plot using the program MolProbity [21] 
showed that 98.2 and 92.6% of the residues lie in the most favourable region and 1.8 and 7.2 % are in 
the additionally allowed regions for the native and fosinoprilat complex respectively. Electron density 
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for residues 36-630 of the expressed protein was visible for both structures, although residues 97-106 
of the fosinoprilat complex were too disordered to model.  
The overall topology of AnoACE2 is similar to that of previously determined structures of 
human ACE domains [25-27] and iACE from Drosophila melanogaster (AnCE) [28, 29], arranged 
predominantly in a helical conformation of two subdomains (Fig. 2A,B). The conserved catalytic Zn2+ 
ion is buried deep inside the active site of AnoACE2 molecule bound to the typical His, His, Glu triad 
(His383, His387 and Glu411 in AnoACE2). In addition, the catalytic glutamate residue (Glu384 in 
AnoACE2) is conserved and adopts an equivalent position and orientation to that seen in other ACE 
analogues. It has previously been observed that sections of the first 100 residues form a ‘lid-like’ 
structure that has been proposed to be involved in ligand entry and exit from the binding site. This 
section is more flexible, and often less well defined than other regions of the structure. Analysis of 
the temperature factors (B-factors) indicates this increased flexibility is also present for AnoACE2 
(residues 36-56 and 86-11λ that comprise the ‘lid-like’ region have an average B-factor of 93.7 Åβ, 
compared to 5γ.λ Åβ for the rest of the protein). 
 
Glycosylation observed in AnoACE2 structures 
The mass-spectrometry results described above indicated that the AnoACE2 molecule contains five 
of the six sequence predicted N-glycosylation sites. Analysis of the electron density maps of the higher 
resolution native AnoACE2 structure confirmed these results showing clear evidence for 
glycosylation on residues Asn69, Asn106, Asn187, Asn212 and Asn327, albeit the density was only 
clear enough to model the glycosylation on residues 69 and 327 (Fig. 3). The glycosylation on Asn69 
showed the typical NAG-NAG-BMA chain. The Asn-linked NAG has a hydrogen bond with Thr71, 
and there is no evidence of a 1-6 linked FUC sugar. The second NAG and BMA sugars are located 
adjacent to symmetry related AnoACE2 molecules that help to fix the orientation of the sugars. In 
addition, the second NAG molecule has a hydrophobic interaction with Phe73. There are patches of 
electron density that indicate the glycosylation chain continues in both the 3- and 6-positions of the 
BMA sugar. Two NAG sugars could be modelled onto Asn327, with the Asn-linked NAG showing 
hydrogen bond interactions with residues Asn566 and Lys569, and some electron density for a 1-6 
linked FUC sugar. The structure showed that residue Asn74 is slightly buried and is located adjacent 
to the glycosylated Asn69, meaning glycosylation on Asn74 would be sterically hindered. Instead the 
electron density maps indicating a water molecule coordinated. The lower resolution fosinoprilat 
complex structure showed similar results, although Asn106 is located in the section not modelled due 
to poor electron density. 
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Binding site of native AnoACE2 
The large range of structures of ACE homologues have shown that their binding sites are not empty 
in the absence of added ligand, or solely occupied by the ligand if it is small [25, 26]. In general, the 
active site zinc ion will bind at least water molecules to complete its coordination sphere, and the C-
terminal carboxy binding pocket always scavenges something from the expression, purification or 
crystallisation conditions. It was therefore not surprising that analysis of the structure of native 
AnoACE2 showed electron density in these regions. However, the extent of ligand observed, 
stretching from the S2' to S1 subsites, was unexpected (Fig. 4A,B). The best explanation for this region 
of electron density is a two residue poly-け-glutamic acid molecule (け-PGA) from the crystallisation 
condition, and this is consistent with the 0.2 % w/v IC50 inhibition of AnoACEβ by け-PGA described 
above. Two conformations of this flexible ligand were modelled into the observed electron density 
(RSCC values of 0.93 for both conformations), although it appears that there may be additional 
conformations or even some instances of alternative ligands.  
Ligplot (Fig. 5A,B) and schematic (Fig. 6A,B) representations of the two け-PGA conformations 
show the interactions involved in binding to AnoACE2. The carboxy terminus of the first glutamic 
acid residue of both conformations of け-PGA is bound in the typical manner to how a peptide binds 
to ACE homologues. There are direct hydrogen bonds to Gln281, Lys511 and Tyr520, and a second 
water mediated interaction with Lys511. The central section of the け-PGA dimer has similarities to a 
peptide bond. In one conformation (Fig. 5A and 6A) there is a series of hydrophobic interactions with 
His353, His513 and Tyr523, as well as hydrogen bonds with Glu384 and the backbone of Ala354, 
whereas in the second conformation there is only one strong interaction, a hydrogen bond with His513 
(Fig. 5B and 6B). In both conformations, what is essentially a carboxy terminus of the second glutamic 
acid molecule forms a bidentate interaction with the active site zinc ion, as well as a hydrogen bond 
with Tyr523 and interactions through a single water molecule with Ala356 and Glu411. Finally, the 
side chain of the second glutamic acid of け-PGA forms interactions through a single water molecule 
with residues His353 and Tyr512 in one conformation (Fig. 5A and 6A), and a series of hydrophobic 
interactions with His353 and Tyr512 in the second conformation (Fig. 5B and 6B). け-PGA is a new 
class of peptide mimic identified to bind to ACE homologues, and we have shown it inhibits 
AnoACE2. This backbone could be used as a starting point to design more potent and selective 
inhibitors. 
 
Fosinoprilat complex with AnoACE2 
AnoACE2 was also crystallized in the presence of fosinopril (the prodrug of fosinoprilat, a known 
inhibitor of mammalian ACE which also inhibits AnoACE2), which under crystallisation conditions 
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hydrolyses to fosinoprilat. Examination of the binding site revealed a large region of electron density 
located adjacent to the zinc ion of the complex structure (Fig. 4C,D). Due to the native structure 
showing that け-PGA from the crystallization conditions can bind in the active site in the same location 
as expected for fosinoprilat, it is important to show that it is not け-PGA bound, and confirm that it is 
indeed fosinoprilat.  Firstly, the shape of the electron density observed is different from that seen for
the native structure, in particular in the S2' subsite and adjacent to the zinc ion. In addition, the electron 
density in the omit map next to the zinc ion is much stronger, being still clearly apparent at 7j level. 
This is more consistent with the phosphinic acid group of fosinoprilat rather than a carboxylic acid 
group of け-PGA. Finally, the placement of fosinoprilat fits both the mFo-DFc omit and 2mFo-DFc 
electron density maps well (apart from the flexible phenyl group as described below), whereas 
refinement with け-PGA does not match the electron density fully and leaves large parts of it 
unexplained (positive density in the difference map). The final model with fosinoprilat modelled gave 
an RSCC value for the ligand of 0.92. 
The inhibitor molecule is buried deep inside the active site pocket (Fig. 2B) and occupies the 
S2' and S1' subsites with the four carbon long chain and phenyl group stretching through the S1 and 2 
subsites. Figure 5C and 6C show the Ligplot and schematic representations of the fosinoprilat binding 
interactions. The carboxy terminus mimic has typical interactions with Gln281, Lys511 and Tyr520, 
and a hydrophobic interaction with His513. The P2' side chain mimic interactions extend deep into the 
S2' subsite and form extensive hydrophobic interactions with Val380, His383 and Tyr523. There are 
additional hydrophobic interactions between His353, His383 and Tyr523 with the P2'- P1' peptide 
backbone mimic, as well as hydrogen bonds with His513 and Tyr523. The phosphinic acid group 
interacts directly with the zinc ion as well as forms hydrogen bonds with His383 and Tyr523. There 
are no close hydrophobic interactions with the four carbon chain of fosinoprilat, and while the terminal 
phenyl ring is sandwiched between Trp357, Ala516 and Val518, it only forms a close, single 
hydrophobic interaction with Trp357. Therefore, this portion of the molecule is not strongly bound 
and explains the relative weak density observed in the electron density maps (Fig. 4C, D). 
The structural data explains the high affinity fosinopril showed for AnoACE2 in the activity 
assays (IC50 of 1.5 nM). Importantly it also showed that fosinopril bound in the ACE active site (S2' 
to S2 subsites), and therefore shows proof of concept for the development of AnoACE2 specific 
inhibitors targeted to the typical ACE binding site. 
 
Discussion 
Comparison of AnoACE2 Structure with Human cACE, nACE and Drosophila AnCE 
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A sequence alignment of the ACE domain of AnoACE2 (598 residues) shares 42.3, 43.6 and 59.7 % 
amino acid identity with the two human sACE domains (nACE-594 residues and cACE-594 residues) 
and AnCE (598 residues) respectively. This is reflected in that all these domains have the same overall 
topology (Fig. 5) with r.m.s. deviations of 0.77Å for AnCE (592 Cg atoms), 1.14Å for nACE (564 Cg 
atoms) and 1.24Å for cACE (567 Cg atoms). The overlay of the structures (the higher resolution native 
AnoACE2 structure has been used for all comparisons with other homologues described in the 
discussion), and the r.m.s. deviations show that AnoACE2 is more closely related to the Drosophila 
homologue AnCE than it is to the human ACE domains of sACE. This is highlighted by two loops 
(residues 148-159 and 542-553 of AnoACE2) that are of equivalent length in AnCE, but 3 and 6 
residues shorter in nACE and cACE respectively (Fig. 7). The C-terminus of these homologues also 
show conservation between AnoACE2 and AnCE, but with nACE and cACE it adopts an orientation 
heading almost 180° in the opposite direction (Fig. 7). Other differences in overall structure are also 
located in loop regions, in particular part of the N-terminal ‘lid-like’ feature, and another region at the 
opposite end of the domain (Fig. 7)
A comparison of the glycosylation sites of AnoACE2 shows that of the five sites confirmed by 
mass spectrometry and crystal structure, only glycosylation of Asn69 is conserved in AnCE and both 
domains of sACE, Glycosylation of AnoACE2 Asn106 is only conserved in cACE, whereas Asn212 
and Asn327 glycosylation is only conserved in AnCE. AnoACE2 Asn187 is only conserved in nACE, 
but it is not glycosylated in nACE. It has previously been shown that not all of the glycosylation sites 
on nACE and cACE are required for activity, and the under-glycosylated domains are routinely used 
for crystallography [24, 30]. It would be interesting for future work to examine the importance of 
individual glycosylation sites to the activity of AnoACE2. 
The active site and the Zn2+ ion binding motif are highly conserved among the four structures. 
However, there are some notable differences in the substrate binding sites, with differences in the S2, 
S1, S1' and S2' subsites being of special interest in relation to inhibitor design as discussed below.  
 
Structural implications of inhibitor binding 
Using the collective structural data on the two sACE domains (nACE – N-domain and cACE – C-
domain), AnCE and the present AnoACE2, it is possible to compare different ACE proteins to look 
for residue and environment differences in AnoACE2 which could be targeted to create specific 
AnoACE2 inhibitors. Studies involving the human nACE and cACE domains have shown that 
although they share a high degree of conservation in the S2ガ to 2 subsites, inhibitors can be designed 
that show a high specificity for individual domain. For example RXP407 is over 3 orders of magnitude 
more potent against nACE [31], whereas RXPA380 is over 3000 times more potent against cACE 
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[32]. Therefore, initially the protein residues forming the binding sub-sites (S2ガ, S1ガ, S1 and S2) 
spanning the catalytic site were compared between the different ACE proteins (Table 3). This shows 
that there are many residues, in addition to the zinc binding motif and the catalytic glutamate, that are 
conserved in all four sub-sites between different ACE homologues. These are residues that could be 
targeted to increase the potency of inhibitors as they are likely to be important in ligand binding, but 
this will not enhance specificity for AnoACE2. 
There are a series of AnoACE2 residues (Glu140, Val380, Tyr391, Tyr512, Ala516 and Val518) 
in the S1ガ, S1 and S2 sub-sites that are only conserved with one or two of the other homologues. 
Targeting a few, or even all, of these residues may help in improving the specificity of potential 
inhibitors for AnoACE2.  
Of particular interest to this study, some residues are unique to AnoACE2, and targeting these 
differences are the most likely route for the rational development of specific inhibitors. These 
variations of the sub-sites have already been shown to give rise to different substrate and inhibitor 
specificities between the different ACE homologues. For example, differences in the S2 sub-site 
between nACE and cACE have been identified as the cause of certain substrate and inhibitor 
specificity differences. In particular the substitution of Phe391 and Glu403 in cACE, to Tyr369 and 
Arg381 in nACE, have been attributed to C-domain selectivity of RXPA380 (Phe391 implicated) [33] 
and specificity for nACE of 33RE (importance of Tyr369) [34] and RXP407 (involvement of both 
Tyr369 and Arg381) [24]. As mentioned above, AnoACE2 has residue Tyr391, which is identical to 
nACE Tyr369, and therefore targeting this residue would only give specificity against cACE (Phe391) 
and AnCE (Phe375). However, Glu403 of cACE and Arg381 of nACE are replaced by Gly403 in 
AnoACE2 and Thr387 in AnCE. While targeting interactions with Gly403 of AnoACE2 could only 
be with conserved backbone atoms, the lack of charge, and extra space available due to a glycine
residue could be exploited. 
In addition to these differences in the S2 sub-site, the S2ガ pocket also shows unique differences 
in AnoACE2. Firstly Tyr527 of AnoACE2 is replaced by a phenylalanine residue in the other 
homologues (Phe505 in nACE, Phe527 in cACE and Phe511 in AnCE). In the structures of nACE, 
cACE and AnCE an acidic residue is conserved (Asp354, Glu376 and Asp360 respectively), although 
they are too far for strong interactions with a typical P2ガ substituent. In contrast, this acidic residue is 
replaced by the longer, basic Arg376 residue in AnoACE2, although in both AnoACE2 structures 
presented here, this arginine residue points away from the S2ガ sub-site. However, it is conceivable that 
an acidic P2ガ moiety would cause a different arginine conformation allowing a salt bridge interaction, 
making Arg376 of AnoACE2 a strong candidate to target for specificity. 
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While typical ACE inhibition has concentrated on the S2ガ, 1ガ, S1 and S2 sub-sites, primarily 
because this would give the usual maximum sized drug-like compound, varying this approach could 
possibly be beneficial by utilizing other regions of the binding pocket that are less well conserved than 
these central sub-sites. For example, captopril is a potent inhibitor of ACE homologues, yet its small 
size only occupies the S2ガ and S1ガ sub-sites along with interaction to the active site zinc ion. Instead of 
the typical mode of extending inhibitors into the non-prime binding lobe to try and gain specificity, 
lengthening the P2ガ moiety would allow interactions with a whole series of poorly conserved residues 
beyond the usual S2ガ sub-site (Table 3, denoted as extended ガ residues). Mutagenesis studies have 
shown that many of these residues are implicated in inhibition specificity between nACE and cACE, 
although this is not through direct interaction with inhibitors, but instead having an effect on the hinge 
region of the ACE domains [35, 36]. Therefore, targeting interactions in this region of AnoACE2 
residues offer an attractive prospect for potent, selective inhibition. 
Another approach would be to anchor one end of an inhibitor by interaction with the active site 
zinc ion, and extend further into the non-prime binding lobe than the typical end at the S2 sub-site. 
Beyond the S3 pocket, residues are much less conserved, making this region an ideal target for 
specificity enhancement. Table 3 highlights four of the more attractive AnoACE2 residues to target, 
with Lys56, Gln59 and Phe360 being unique and Lys78 only being conserved in AnCE. 
 
Conclusion 
The first AnoACE2 structures presented here highlight the differences between the insect and 
mammalian enzymes in order to begin the design of a range of ‘iACE-enhanced’ inhibitors. They 
additionally provide information to allow specificity between Anopheles and Drosophila insect 
species. This level of detailed knowledge makes AnoACE2 an attractive target for applying structure-
based drug design to developing potent and, importantly, highly selective inhibitors which could be 
used as insecticides. These could be presented to the larvae Anopheles gambiae encapsulated in a 
particulate form to maximize oral uptake in these filter feeders. 
 
Database Depositions 
The atomic co-ordinates and structure factors have been deposited in the RCSB Protein Data Bank 
with accession numbers 6S1Y and 6S1Z. The atomic co-ordinates and experimental data will be 
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Table 1. IC50 and confidence interval (CI) values for the inhibition of AnoACE2 activity.  
NB. け-PGA is written as % w/v due to it being a mix of different length polymers. 
 
Inhibitor IC50 (nM or % w/v) 95% CI (nM or % w/v) 
Fosinoprilat 1.5 nM 0.7-3.2 nM 
Lisinopril 16 nM 13-19 nM 
Captopril 5.2 nM 3.9-6.8 nM 
Enalaprilat 2.0 nM 0.92-4.3 nM 




Table 2. X-ray data collection and refinement statistics. Inner shell, overall and outer shell statistics 










Space group P622 2 P622 2 
Cell dimensions (a,b,c) 
angles (g,く,け) 
161.0, 161.0, 121.9 Å 
90.0, 90.0, 120.0° 
166.7, 166.7, 117.5 Å 
90.0, 90.0, 120.0° 
Molecules/asymmetric unit 1 1 
Total / Unique reflections 1,821,323/47,663 2,623,791/33,809 
Completeness (%) [99.9] 100.0 (100.0) [100.0] 100.0 (100.0) 
Rmerge [0.075] 0.316 (6.955) [0.038] 0.149 (1.220) 
Rpim [0.014] 0.052 (1.121) [0.005] 0.017 (0.137) 
<I/j(I)> [39.5] 11.0 (0.9) [114.0] 24.8 (4.7) 
CC1/2 [0.998] 0.998 (0.551) [1.000] 1.000 (0.622) 
Multiplicity [30.8] 38.2 (39.2) [63.7] 77.3 (79.8) 
Refinement statistics 
Rwork/Rfree 0.194/0.241 0.294/0.337 
Rmsd in bond lengths (Å) 0.008 0.002 
Rmsd in bond angles (°) 0.960 0.496 
Ramachandran statistics (%) 
Favoured 98.2 92.6 
Allowed 1.8 7.2 
Outliers 0.0 0.2 
Average B- factors (Å2) 
Protein 57.7 95.1 
Ligand 74.5 101.7 
Water 47.7 51.2 
Number of atoms 
Protein 9605 9397 
Ligand 233 136 
Water 199 25 
PDB code 6S1Y 6S1Z 
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Table 3. Comparison of binding site residues. Residues involved in forming the sub-sites for 
AnoACE2, cACE and nACE of sACE, and AnCE. Typical ACE inhibitors are designed to target the 
S2ガ, S1ガ, S1 and S2 sub-sites, although there are many structural differences beyond a typical S2ガ 
sidechain length and the S3 sub-site. A selection of these residues are included below. Exガ stands for 
Extendedガ. 
 
 AnoACE2 AnCE cACE nACE 
S2ガ, S1ガ, S1, S2 sub-sites 
Fully conserved 
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Figure 1. AnoACE2 glycosylation sites were identified by mass spectrometry. (A) AnoACE2 was 
digested with chymotrypsin (left) or trypsin (right). Chymotrypsin and trypsin peptides are shown 
bold with potential N-linked glycosylation sites highlighted (green: covered, glycosylated; red: 
covered, not glycosylated; yellow: not covered). (B) Mass spectra for each potential glycosylation 









Figure 2. AnoACE2 crystal structures. Schematic representation of the overall fold of (A) native 
and (B) fosinoprilat complex AnoACEβ structures. け-PGA dimer and fosinoprilat are depicted with 
light green and light blue sticks respectively. Zinc ions are shown as lilac spheres, with g-helices and 
く-strands shown in rose and dark cyan respectively. Loop regions have been smoothed for clarity. 









Figure 3. Predicted AnoACE2 N-linked glycosylation sites. The native AnoACE2 crystal structures 
shows evidence for glycosylation on five of the six predicted N-linked glycosylation sites (on 
asparagines 69, 106, 187, 212 and 327), with Asn74 unglycosylated being partially buried and 
coordinated to a water molecule. Sufficient density is observed to model sugars for Asn69 and Asn327 
glycosylation. g-helices and く-strands shown in rose and dark cyan respectively, with the 2mFo-DFc 
electron density map shown in blue (contoured at 1j level). NAG and BMA are N-acetylglucosamine 









Figure 4. AnoACE2 ligand binding sites. Close up views of (A+B) け-PGA dimer (two alternate 
conformations) and (C+D) fosinoprilat binding sites overlayed with the final 2mFo-DFc electron 
density map (blue, contoured at 1j level) and the mFo-DFc electron density omit map (green, 
contoured at 3 and 2.5j level for け-PGA and fosinoprilat respectively). け-PGA dimer and fosinoprilat 
are depicted with light green and light blue sticks respectively. Zinc ions are shown as lilac spheres, 









Figure 5. Ligplot representation for け-PGA dimer and fosinoprilat AnoACE2 complexes. 
Binding site interactions of (A) け-PGA conformation 1, (B) け-PGA conformation 2 and (C) 
fosinoprilat. H-bond/electrostatic and hydrophobic interactions are shown in green and red dotted 
lines respectively, water molecules as red spheres, and residues solely involved in hydrophobic 










Figure 6. Binding site interactions for け-PGA dimer and fosinoprilat. AnoACE2 complexes. 
Schematic representation of (A) け-PGA conformation 1, (B) け-PGA conformation 2 and (C) 
fosinoprilat binding sites showing the interactions involved with the ligands. H-bond/electrostatic and 
hydrophobic interactions are shown in green and red dotted lines respectively, and water molecules 










Figure 7. AnoACE2 overall structure comparison with ACE homologues. AnoACE2 green 
(Native structure), AnCE (2X8Y) red, nACE (6H5X) purple, tACE (6H5W) blue. Inset is the C-
terminus region that has been enlarged and rotated for clarity. 
 
 
 
 
